Riskpilot← Back to searchSign inGet full accessOftalmus Läkarkonsult AB
ABDissolvedOrg 5593013146Medical specialists activities · NACE 8622Est. 20210 employees
Revenue 2025
SEK 4,4M
+3% vs 2024
EBITDA margin
24.7%
+5% vs 2024
Equity ratio
2.6%
Financial strength
Net profit 2025
SEK 14K
0 employees
| Revenue | SEK 4,4M | +3% |
| EBITDA | SEK 1,1M | +5% |
| Net profit | SEK 14K | — |
| Total assets | SEK 2M | +5% |
| Equity | SEK 50K | +40% |
| Employees | 0 | — |
Legal name
Oftalmus Läkarkonsult AB
Org number
5593013146
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 februari 2021
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsulttjänster inom ögonkirurgi, bedriva allmän hälso- och sjukvård, föreläsningar, konsultation och rådgivning inom läkemedel- och sjukvårdsbranschen och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3 633 | 3 862 | 4 241 | 4 359 |
| Staff expenses | — | — | — | — | −1 398 |
| EBITDA | −4 | 1 272 | 1 365 | 1 021 | 1 075 |
| Depreciation & amort. | −0 | −0 | −6 | −19 | −23 |
| EBIT | −4 | 1 272 | 1 359 | 1 002 | 1 052 |
| Net financials | — | — | −1 | 1 | 2 |
| Profit before tax | −2 | 0 | 30 | 25 | 50 |
| Tax | −0 | −14 | −28 | −25 | −36 |
| Net profit | −2 | −14 | 2 | 0 | 14 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 83 | 1 506 | 1 874 | 1 867 | 1 965 |
| Equity | 48 | 34 | 36 | 36 | 50 |
| Long-term debt | 0 | 1 271 | 1 629 | 1 632 | 1 686 |
| Short-term debt | 35 | 200 | 208 | 198 | 228 |
| Total debt | 35 | 1 471 | 1 837 | 1 830 | 1 915 |
EBITDA margin
24.7%
This company
15.8%
Market median
+56% vs market
20212025
Equity ratio
2.6%
This company
38.2%
Market median
-93% vs market
20212025
Return on equity
28.0%
This company
18.4%
Market median
+52% vs market
20212025
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20212025
Asset turnover
2.22×
This company
1.12×
Market median
+98% vs market
20212025
Debt / equity
37.92×
This company
0.62×
Market median
-6016% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JR Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Optalmica Holding AB
Oftalmus Läkarkonsult AB Board members of Oftalmus Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens Roland Brehme | Audit | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Zoi Papaioannou | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Nikolaos Merkoudis | Board of Directors | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |